In this episode of Inside the Lab, host David Ritter kicks off a new series on corporate responsibility with a timely conversation about Green Labs. Joined by Dr. Ilyssa Gordon and Dr. Moira Larsen, the discussion revisits how far laboratory sustainability has come since Dr. Gordon’s 2021 appearance on the show and examines what has changed over the last four years.

The episode explores what “green labs” really mean in the context of clinical and pathology laboratories, from life-cycle assessments that quantify the carbon footprint of common workflows to system-level strategies that integrate sustainability into corporate responsibility frameworks. Dr. Gordon shares insights from her research on the environmental impact of GI biopsy processing and discusses how data-driven approaches can influence decision-making at the bench. Dr. Larsen outlines how green initiatives must be built into lab’s missions and financials in order to truly take hold, as well as the importance of partnering with aligned partners when sourcing materials.

Throughout the conversation, the guests emphasize practical, achievable actions—both at the institutional and individual levels—while addressing the realities facing today’s lab professionals. The episode concludes on an optimistic note, highlighting what’s currently inspiring leaders in laboratory sustainability and reinforcing the idea that meaningful progress is possible, even in resource-constrained environments.

The current landscape of testing for NSCLC is complex, with many new biomarkers emerging rapidly, more points during which testing is possible, and precision drug treatments available on the basis of findings from biomarker testing. While promising for patients, the result of this rapidly changing landscape is confusion from interdisciplinary care teams as to what testing is necessary and when, who in multidisciplinary care teams should be ordering new tests and when, and what workflows are necessary for labs. Host David Ritter, MA is joined by Dr. Ying-Chun Lo and Dr. Mamatha Chivuluka to discuss what things pathologists and lab professionals need to know about emerging biomarkers for NSCLC.

In this conversation, the panel reflects on how NSCLC biomarker testing has evolved over the past decade, highlighting the shift from limited, sequential testing to guideline-recommended broad molecular profiling. Drs. Lo and Chivuluka explore the clinical relevance of emerging biomarkers such as HER2, TROP2, and HER3, and discuss how new targeted therapies are influencing testing strategies in real-world practice. They also examine practical considerations for laboratories, including platform selection across IHC, PCR, and NGS, approaches to tissue stewardship in small lung biopsies, and the growing leadership role of pathologists in multidisciplinary teams to ensure timely, guideline-concordant, and equitable access to biomarker testing for patients with NSCLC.

Host David Ritter, MA is joined by Lotte Mulder, PhD and Kamran Mirza, MD, PhD, FASCP to discuss their new book, Mia the Marvelous Lab Explorer. The adventure follows Mia, a superhero and scientist, who uses laboratory science to explain why a friend has fallen ill with leukemia. The book targets children ages 5 to 9 years and balances striking entertaining and engaging tone with explaining scientific concepts accurately to a younger audience. Their conversation of the book expands into strategies for fostering engagement in laboratory science across age groups, how children’s literature can highlight the role of the lab to parents as well as younger readers, and how the format of a children's book fits into the undeclared student to laboratory professional pipeline ASCP is working to create.

Additionally, there is currently a fundraiser underway to donate 1,000 copies of the book to pediatricians' offices, libraries, and schools under the hashtag #MissionMarvelous. If you would like to contribute to the fundraiser, you can do so here: miathemarvelous.com. The fundraiser runs through February 16, 2026.